此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

I-DXd 与 Atezolizumab(加或不加卡铂)联合作为广泛期小细胞肺癌受试者的一线诱导或维持的研​​究 (IDeate-Lung03)

2026年9月28日 更新者:Daiichi Sankyo

一项 1b/2 期、多中心、开放标签研究,研究 Ifinatamab Deruxtecan (I-DXd)(一种 B7-H3 抗体药物偶联物 (ADC))与 Atezolizumab 联合或不联合卡铂作为一线诱导或维持治疗,广泛期小细胞肺癌 (ES-SCLC) 受试者 (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

研究概览

详细说明

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

研究类型

介入性

注册 (估计的)

123

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Himeji-shi、日本、670-8520
        • 招聘中
        • NHO Himeji Medical Center
      • Hirakata-shi、日本、573-1191
        • 招聘中
        • Kansai Medical University Hospital
        • 接触:
          • Principal Investigator
      • Kashiwa、日本、277-8577
        • 招聘中
        • National Cancer Center Hospital East
        • 接触:
          • Principal Investigator
      • Kumamoto、日本、861-4193
        • 招聘中
        • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
        • 接触:
          • Principal Investigator
      • Kōtoku、日本、135-8550
        • 招聘中
        • The Cancer Institute Hospital of Jfcr
        • 接触:
          • Principal Investigator
      • Nagaizumi-cho、日本、411-8777
        • 招聘中
        • Shizuoka Cancer Center
        • 接触:
          • Principal Investigator
      • Niigata、日本、951-8566
        • 招聘中
        • Niigata Cancer Center Hospital
        • 接触:
          • Principal Investigator
      • Okayama、日本、700-8558
        • 招聘中
        • Okayama University Hospital
        • 接触:
          • Principal Investigator
      • Tokushima、日本、770-8503
        • 招聘中
        • Tokushima University Hospital
      • Toyoake-shi、日本、470-1192
        • 招聘中
        • Fujita Health University Hospital
      • Ōsaka-sayama、日本、589-8511
        • 招聘中
        • Kindai University Hospital
        • 接触:
          • Principal Investigator
      • Lille、法国、59037
        • 招聘中
        • Hopital Albert Calmette - Chu Lille
        • 接触:
          • Principal Investigator
      • Lyon、法国、69008
        • 招聘中
        • Centre Léon Bérard
        • 接触:
          • Principal Investigator
      • Marseille、法国、13005
        • 招聘中
        • Hôpital de la Timone
        • 接触:
          • Principal Investigator
      • Paris、法国、75005
        • 招聘中
        • Institut Curie - Site de Paris
        • 接触:
          • Principal Investigator
      • Paris、法国、75020
        • 招聘中
        • Hopital Tenon
        • 接触:
          • Principal Investigator
      • Rennes、法国、35000
        • 招聘中
        • Chu Rennes - Hopital Pontchaillou
        • 接触:
          • Principal Investigator
      • Saint-Herblain、法国、44805
        • 招聘中
        • CHU Nantes - Hôpital Guillaume et René Laënnec
        • 接触:
          • Principal Investigator
      • Suresnes、法国、92151
        • 招聘中
        • Hôpital Foch
        • 接触:
          • Principal Investigator
      • Villejuif、法国、94805
        • 尚未招聘
        • Institut Gustave Roussy
        • 接触:
          • Principal Investigator
    • Alabama
      • Birmingham、Alabama、美国、35233
        • 招聘中
        • University of Alabama -Birmingham
        • 接触:
          • Principal Investigator
    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • Mayo Clinic Arizona
        • 接触:
          • Principal Investigator
    • California
      • Los Angeles、California、美国、90095
        • 尚未招聘
        • David Geffen School of Medicine
        • 接触:
          • Principal Investigator
      • Newport Beach、California、美国、92663
        • 招聘中
        • Hoag Memorial Hospital Presbyterian
        • 接触:
          • Principal Investigator
    • Florida
      • Jacksonville、Florida、美国、32224
        • 招聘中
        • Mayo Clinic-Jacksonville
        • 接触:
          • Principal Investigator
      • Orlando、Florida、美国、32804
        • 招聘中
        • Advent Health Orlando
        • 接触:
          • Principal Investigator
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
        • 接触:
          • Principal Investigator
    • Michigan
      • Detroit、Michigan、美国、48202
        • 主动,不招人
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • Regents of the University of Minnesota
        • 接触:
          • Principal Investigator
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic
        • 接触:
          • Principal Investigator
    • New Hampshire
      • Lebanon、New Hampshire、美国、03766
        • 招聘中
        • Dartmouth-Hitchcock Medical Center
        • 接触:
          • Principal Investigator
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
        • 招聘中
        • Astera Cancer Care
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • John Theurer Cancer Center At Hackensack Umc
        • 接触:
          • Principal Investigator
    • New York
      • Mineola、New York、美国、11501
        • 招聘中
        • NYU Langone Hospital - Long Island
        • 接触:
          • Principal Investigator
      • Mineola、New York、美国、11501
        • 招聘中
        • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
        • 接触:
          • Principal Investigator
      • New York、New York、美国、10021
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
        • 接触:
          • Principal Investigator
      • New York、New York、美国、10461
        • 招聘中
        • Montefiore Medical Center
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Hervert Irving Comprehensive Cancer Center
        • 接触:
          • Principal Investigator
    • Pennsylvania
      • Lancaster、Pennsylvania、美国、17601
        • 招聘中
        • Lancaster General Hospital - Ann B Barshinger Cancer Institute
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • University of Pennsylvania, Abramson Cancer Center
      • Philadelphia、Pennsylvania、美国、19107
        • 招聘中
        • Thomas Jefferson University Hospital - Central
        • 接触:
          • Principal Investigator
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Scri Oncology Partners
        • 接触:
          • Principal Investigator
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Next Virginia
        • 接触:
          • Principal Investigator
    • Washington
      • Vancouver、Washington、美国、98684
        • 招聘中
        • Northwest Cancer Specialists, P.C.-Vancouver
        • 接触:
          • Principal Investigator
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • 招聘中
        • Medical College of Wisconsin
        • 接触:
          • Principal Investigator
      • Barcelona、西班牙、08036
        • 招聘中
        • Hospital Clinic de Barcelona
        • 接触:
          • Principal Investigator
      • Barcelona、西班牙、8035
        • 招聘中
        • Hospital Universitari Vall D'Hebron
        • 接触:
          • Principal Investigator
      • Girona、西班牙、17007
        • 招聘中
        • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
        • 接触:
          • Principal Investigator
      • L'Hospitalet de Llobregat、西班牙、08908
        • 招聘中
        • ICO l'Hospitalet - Hospital Duran i Reynals
        • 接触:
          • Principal Investigator
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre
        • 接触:
          • Principal Investigator
      • Madrid、西班牙、28007
        • 招聘中
        • Hospital General Universitario Gregorio Marañon
        • 接触:
          • Principal Investigator
      • Madrid、西班牙、28034
        • 招聘中
        • Hospital Universitario Ramon Y Cajal
        • 接触:
          • Principal Investigator
      • Madrid、西班牙、28223
        • 招聘中
        • Next Madrid
        • 接触:
          • Principal Investigator
      • Málaga、西班牙、29010
        • 招聘中
        • Hospital Regional Universitario de Malaga
        • 接触:
          • Principal Investigator
      • Seville、西班牙、41009
        • 招聘中
        • Hospital Universitario Virgen Macarena
        • 接触:
          • Principal Investigator
      • Seville、西班牙、41013
        • 招聘中
        • Hospital Universitario Virgen Del Rocio
        • 接触:
          • Principal Investigator
      • Vigo、西班牙、36312
        • 招聘中
        • Hospital Alvaro Cunqueiro
        • 接触:
          • Principal Investigator

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

  3. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

  6. For Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

  7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization).

  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.

  9. A female subject of childbearing potential (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  7. Has clinically significant corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  15. Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled human immunodeficiency virus (HIV) infection.
  18. Has active or uncontrolled hepatitis B or C virus (HBV or HCV) infection.
  19. Has history of autoimmune disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a live vaccine within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

实验性的:Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

Intravenous administration

实验性的:Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

Intravenous administration

实验性的:Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

实验性的:Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

实验性的:Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

Intravenous administration

实验性的:Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

其他名称:
  • I-DXd

Intravenous administration

Intravenous administration

研究衡量的是什么?

主要结果指标

结果测量
大体时间
I-DXd 联合 Atezolizumab 联合或不联合卡铂后报告剂量限制性毒性的参与者数量(A 部分)
大体时间:周期1第1天至周期1第21天(每个周期为21天)
周期1第1天至周期1第21天(每个周期为21天)
I-DXd 联合 Atezolizumab 联合或不联合卡铂后出现治疗中出现的不良事件的参与者总数(A 部分和 B 部分)
大体时间:基线长达 37 个月
基线长达 37 个月

次要结果测量

结果测量
措施说明
大体时间
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
大体时间:From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response [CR] or confirmed partial response [PR]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
大体时间:Baseline up to approximately 37 months

The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Baseline up to approximately 37 months
Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
大体时间:From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

Time from the date of enrollment/randomization to the date of death due to any cause.

From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months
Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd
大体时间:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd
大体时间:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd
大体时间:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
大体时间:Baseline up to approximately 37 months

The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

Baseline up to approximately 37 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Global Clinical Leader、Daiichi Sankyo

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月22日

初级完成 (估计的)

2027年7月20日

研究完成 (估计的)

2028年2月20日

研究注册日期

首次提交

2024年1月2日

首先提交符合 QC 标准的

2024年4月8日

首次发布 (实际的)

2024年4月12日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • DS7300-189
  • 2023-509629-36 (其他标识符:EU CT)
  • 2031240089 (其他标识符:JRCT)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 共享时间框架

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 共享访问标准

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅